PLATO ACT5
Is a seamless randomised pilot, phase II and phase III trial that compares standard-dose CRT (53.2Gy in 28 fractions) with two higher doses of CRT (58.8Gy and 61.6Gy, both in 28 fractions), in patients with locally advanced anal cancer, to see if giving a higher dose of radiotherapy reduces the chance of the cancer coming back, whilst not causing too many extra side effects. Both of the two higher-dose experimental arms will be taken into the phase III component of the study.
ACT5 Recruitment
439 Patients (estimated end of recruitment: Aug 2023)